Immunity to melanin and to tyrosinase in melanoma patients, and in people with vitiligo - Wikidata - wikimedia - TriplyDB

Immunity to melanin and to tyrosinase in melanoma patients, and in people with vitiligo

Immunity to melanin and to tyrosinase in melanoma patients, and in people with vitiligo

http://www.wikidata.org/entity/Q34352772

about

Alternaria scalp infection in a patient with alopecia areata. Coexistence or causative relationship?Anti-Melanoma immunity and local regression of cutaneous metastases in melanoma patients treated with monobenzone and imiquimod; a phase 2 a trial.The antibody response against MART-1 differs in patients with melanoma-associated leucoderma and vitiligo.

P2860

Q42091211-821DAADB-4DED-4BC4-8F9D-1512F79FD8F6 Q52597538-10108288-BBA5-44D9-88BD-304BED75F83B Q55058396-4C987DBE-C0B1-4D46-AA7E-3101C265A2D1

P2860

Immunity to melanin and to tyrosinase in melanoma patients, and in people with vitiligo

http://www.wikidata.org/entity/Q34352772

description

2012 nî lūn-bûn

@nan

2012 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

name

Immunity to melanin and to tyrosinase in melanoma patients, and in people with vitiligo

@ast

Immunity to melanin and to tyrosinase in melanoma patients, and in people with vitiligo

@en

Immunity to melanin and to tyrosinase in melanoma patients, and in people with vitiligo

@nl

type

label

Immunity to melanin and to tyrosinase in melanoma patients, and in people with vitiligo

@ast

Immunity to melanin and to tyrosinase in melanoma patients, and in people with vitiligo

@en

Immunity to melanin and to tyrosinase in melanoma patients, and in people with vitiligo

@nl

prefLabel

Immunity to melanin and to tyrosinase in melanoma patients, and in people with vitiligo

@ast

Immunity to melanin and to tyrosinase in melanoma patients, and in people with vitiligo

@en

Immunity to melanin and to tyrosinase in melanoma patients, and in people with vitiligo

@nl

P1433

Q34352772-372A9B68-6BB7-45AB-A117-17C3694BB34B

P1476

Q34352772-AA5356FC-63EB-4AB4-9154-8F884FEB7FFA

P2093

Q34352772-02D9D697-BE70-463F-8675-F1DF639FF83E

Q34352772-1CF00A6A-B488-492C-AEB2-A8E45C15053C

Q34352772-1D90918E-7CD1-4262-9BBD-BFD0AFEE1BBD

Q34352772-37BC7A34-38A7-4884-A289-981643A8F03A

Q34352772-4711A621-B053-465C-9028-EE7213204A0F

Q34352772-6AD353A9-D091-4926-BB06-DDFD5E26EFCB

Q34352772-70B0BBB0-3CBB-41A3-8480-125799931063

Q34352772-734F178C-559D-4DF9-8753-05187C1FEA99

Q34352772-B821B302-14D4-42F2-A733-5F540E662EA1

Q34352772-B90E0536-08C8-48D9-B370-681F8BD820B3

P2860

Q34352772-136A3DA8-8617-4197-A121-92FE642C8CE6

Q34352772-28E726B0-0191-4C2A-9173-736C2309C095

Q34352772-3201F637-5FEF-407C-A0F0-0C9FBE95FA00

Q34352772-39C905C4-ECAF-44D0-8B61-73DE8ED466AA

Q34352772-3A6A62EB-0987-425B-B500-5A4F534A49AA

Q34352772-45FB3B3A-C136-48EC-8BA9-BF3A4F78CD8E

Q34352772-4D25889C-C031-4210-8053-7D8C7F02CC3D

Q34352772-4F8C6FE9-C454-4C5C-884C-38E8A6319FAA

Q34352772-4FCFB8C9-C2BB-43D1-A64B-0B4BE1C21A85

Q34352772-59089CEB-9DC7-4563-8A66-AC07FC7F8E98

P2888

Q34352772-E7C958E0-B6A2-46C9-BC7B-364CAD41CEE2

P304

Q34352772-53256F38-C1C2-42EB-816E-1697186AE4A0

P31

Q34352772-97D23E9B-8DC7-4396-B394-CE1F0D1378DC

P356

Q34352772-AC53C4A2-96AE-4A56-B8F4-933A4FB4A5E9

P478

Q34352772-F199616D-0C2A-4024-8AC3-ED94DEE87C3F

P50

Q34352772-5A4D1FB0-EC8F-494C-81DA-6EE0D7652820

Q34352772-C64B477C-10FC-4455-9C14-E5E422A88582

Q34352772-DF3C0AEA-A20A-43AD-8049-93490A61CACE

P577

Q34352772-C00380C2-359F-4013-93E2-8CDC4BF30D85

P5875

Q34352772-8C21F124-1D59-4B1B-A108-37961FD0DED6

P6179

Q34352772-5E2A5371-D49C-409B-875A-39BCDFBE5DBA

P698

Q34352772-60646937-FEEE-479D-A790-195EE303FF7E

P932

Q34352772-706D8C05-7178-4CCE-8E22-3BFB87C74772

P356

1472-6882-12-109

P1433

BMC Complementary and Alternative Medicine

P1476

Immunity to melanin and to tyrosinase in melanoma patients, and in people with vitiligo

@en

P2093

Aleksandra Erić-Nikolić

http://www.w3.org/2001/XMLSchema#string

Ana Damjanović

http://www.w3.org/2001/XMLSchema#string

Ana Vuletić

http://www.w3.org/2001/XMLSchema#string

Branka Kolundžija

http://www.w3.org/2001/XMLSchema#string

Danijela Dobrosavljević

http://www.w3.org/2001/XMLSchema#string

Ivana Filipović-Lješković

http://www.w3.org/2001/XMLSchema#string

Janko Pralica

http://www.w3.org/2001/XMLSchema#string

Marija Dorđić

http://www.w3.org/2001/XMLSchema#string

Miomir Sašić

http://www.w3.org/2001/XMLSchema#string

Sanvila Rašković

http://www.w3.org/2001/XMLSchema#string

P2860

Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy

New perspectives on the role of vitiligo in immune responses to melanoma

Mechanisms involved in down-regulation of intestinal IgA in rats by high cocoa intake

Different levels of humoral immunoreactivity to different wheat cultivars gliadin are present in patients with celiac disease and in patients with multiple myeloma.

FRET microscopy autologous tumor lysate processing in mature dendritic cell vaccine therapy

Immunotherapy for metastatic solid cancers

Humoral immunity to cow's milk proteins and gliadin within the etiology of recurrent aphthous ulcers?

Expansion of CD16-negative natural killer cells in the peripheral blood of patients with metastatic melanoma.

Therapeutic options in cutaneous melanoma: latest developments.

Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab

P2888

1472-6882-12-109

P304

109

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1472-6882-12-109

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

Nađa Grozdanić

P577

2012-07-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230571892

http://www.w3.org/2001/XMLSchema#string

P6179

1031801352

http://www.w3.org/2001/XMLSchema#string

P698

22834951

http://www.w3.org/2001/XMLSchema#string

P932

3457868

http://www.w3.org/2001/XMLSchema#string